April 26, 2024
Bio
Hanmi Pharma denies suspension of clinical trials
[THE INVESTOR] Hanmi Pharmaceutical on Dec. 7 denied media reports that its clinical trials have been halted for a new drug candidate, technology for which was exported to Janssen for US$915 million.
The drug is a novel diabetes and obesity treatment.
The reports quoted a post on clinicaltrials.gov that said, “This study has suspended participant recruitment,” which according to the pharma firm refereed to a temporary suspension in recruiting patients and not the trials of JNJ-64565111 themselves.
The partnership with Janssen remains unchanged, Hanmi added.
Janssen has been conducting phase 1 clinical trials since July. The pharmaceutical arm of Johnson & Johnson has not released a statement yet.
By Hwang You-mee (glamazon@heraldcorp.com)
The drug is a novel diabetes and obesity treatment.
The reports quoted a post on clinicaltrials.gov that said, “This study has suspended participant recruitment,” which according to the pharma firm refereed to a temporary suspension in recruiting patients and not the trials of JNJ-64565111 themselves.
The partnership with Janssen remains unchanged, Hanmi added.
Janssen has been conducting phase 1 clinical trials since July. The pharmaceutical arm of Johnson & Johnson has not released a statement yet.
By Hwang You-mee (glamazon@heraldcorp.com)
